The predictive and prognostic role of the different CD137+ T cell subsets were further analyzed in the 55 NSCLC patients treated with immunotherapy ± chemotherapy as first-line treatment (Fig. 3). This evidence concerns the gene TNFRSF9 and non-small cell lung carcinoma.